CD274 and cardiovascular disorder: Recent studies have highlighted the role of the PD-1/PD-L1 pathway in cardiovascular diseases, suggesting that increased PD-L1 expression in the myocardium may serve as a biomarker for patients at risk of developing cardiac complications following ICI therapy (30).